Potential of dual time point fdg-pet imaging in differentiating malignant from benign pleural disease

Molecular Imaging and Biology

Volumn 11, Issue 5, 2009, Pages 369-378

  Mavi, Ayse ^a   Basu, Sandip ^a,b   Cermik, Tevfik F ^a   Urhan, Muammer ^a   Bathaii, Mehdi ^a   Thiruvenkatasamy, Dhurairaj ^a   Houseni, Mohamed ^a   Dadparvar, Simin ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

18F FDG PET; Benign pleural disease; Dual time point imaging; Inflammation; Malignant pleural mesothelioma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA BIOPSY; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLEURAL DISEASES; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 68449102942     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0212-5     Document Type: Article

References (40)

1. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H (2004) PET: A revolution in medical imaging. Radiol Clin North Am 42(6):983-1001
2. Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412-1417
3. Hustinx R, Smith RJ, Benard F et al (1999) Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26:1345-1348
4. Matthies A, Hickeson M, Cuchiara A, Alavi A (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871-875
5. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114:713-722
6. Buck A, Schirrmeister H, Kuhn T et al (2002) FDG uptake in breast cancer: Correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317-1323
7. Price B (1997) Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 145:211-218
8. Bertram P, Adam W (2004) Mesothelioma trends in the United States: An update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol 159:107-112
9. Muller N (1993) Imaging of the pleura. Radiology 186:297-309
10. Falaschi F, Boraschi P, Musante F, Volpini F, D'Alessandro F, Torri T, Barbieri L (1992) The computed tomographic diagnosis of malignant pleural mesothelioma. A multicenter study. Radiol Med (Torino) 84(1-2):43-7
11. Rusch V, Godwin J, Shuman W (1988) The role of computed tomography scanning in the initial assessment and follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 96:171-177
12. Metintas M, Ozdemir N, Isiksoy S et al (1995) CT-guided pleural biopsy in the diagnosis of malignant mesothelioma. J Comput Assist Tomogr 19:370-374
13. Collins T, Sahn S (1987) Thoracocentesis. Clinical value, complications, technical problems, and patient experience. Chest 91:817-822
14. Menzies R, Charbonneau M (1991) Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 114:271-276
15. Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F et al (2000) 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. Eur J Cardiothorac Surg 17:377-383
16. Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, Koeter GH et al (2004) PET for the evaluation of pleural thickening observed on CT. J Nucl Med 45:995-998
17. Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D et al (2002) Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 122:1918-1924
18. Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF (1997) Evaluation of pleural diseases with FDG-PET imaging: Preliminary report. Thorax 52:187-189
19. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ (1994) The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification? J Nucl Med 35:1308-1312
20. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26:22-30
21. Mavi A, Urhan M, Yu JQ et al (2006) Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 47(9):1440-1446
22. Mavi A, Lakhani P, Zhuang H et al (2005) Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am 43(1):1-21
23. Basu S, Mavi A, Cermik T, Houseni M, Alavi A (2008) Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: Does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Mol Imaging Biol 10(1):62-66
24. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 44:540-548
25. Mavi A, Cermik TF, Urhan M, Yu JQ, Zhuang H, Alavi A (2006) Dual time point FDG-PET imaging can help distinguishing residual invasive tumor from post biopsy inflammation in newly diagnosed breast cancer. 9th Congress of World Federation of Nuclear Medicine & Biology. World J Nucl Med (WJNM) 5(supp 1):S77
26. Bedigian MP, Benard F, Smith RJ, Karp JS, Alavi A (1998) Whole-body positron emission tomography for oncology using singles transmission scanning with segmentation and ordered subsets expectation maximization (OS-EM) reconstruction. Eur J Nucl Med 25:659-661
27. Aisner J (1995) Current approach to malignant mesothelioma of the pleura. Chest 107:332S-344S
28. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108(4):1122-1128
29. Pisani R, Colby T, Williams D (1988) Malignant mesothelioma of the pleura. Mayo Clin Proc 63:1234-1244
30. Sugarbaker DJ, Jaklitsch MT, Liptay MJ (1995) Mesothelioma and radical multimodality therapy: Who benefits? Chest 107:345S-350S
31. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF (2000) FDG PET of pleural effusions in patients with non-small cell lung cancer. Am J Roentgenol 175:245-249
32. Falaschi F, Battolla L, Mascalchi M, Cioni R, Zampa V, Lencioni R et al (1996) Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am J Roentgenol 166:963-968
33. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R et al (2000) Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 120:128-133
34. Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C et al (2004) Role of F-18-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm 19:149-154
35. Patz EF Jr., Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE et al (1993) Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487-490
36. Rusch VW, Venkatraman ES (1999) Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68:1799-1804
37. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1999) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241-1245
38. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P et al (2002) Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 32:293-321
39. Haberkorn U (2004) Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 45 Suppl 1:S73-S76
40. Nakamoto Y, Higashi T, Sakahara H et al (2000) Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89:2547-2554